Opko to Purchase OURLab CLIA Lab to Support US Launch of 4Kscore Prostate Cancer Dx | GenomeWeb

Opko Health has entered a definitive agreement to acquire Prost-Data, which does business as OURLab, a Nashville, Tenn.-based CLIA laboratory.

The acquisition will provide Opko with a platform to support the US commercial launch of its 4Kscore protein biomarker prostate cancer test, the company said. Opko is planning a "near-term" US launch of the test as a laboratory-developed test.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.